CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in a Virtual Investor CEO Connect segment. The event, scheduled for Monday, August 26, 2024, at 12:00 PM ET, will feature CEO John Climaco.
The segment will include a brief presentation by Mr. Climaco, followed by an interactive Q&A session. Investors can submit questions live during the event or in advance via email to cnsp@jtcir.com. The live video webcast will be available on the company's website, with a replay accessible for 90 days following the presentation.
CNS Pharmaceuticals (NASDAQ: CNSP), un'azienda biofarmaceutica focalizzata sullo sviluppo di trattamenti innovativi per i tumori cerebrali e del sistema nervoso centrale, ha annunciato la sua partecipazione a un segmento Virtual Investor CEO Connect. L'evento, previsto per lunedì 26 agosto 2024, alle 12:00 PM ET, vedrà come protagonista il CEO John Climaco.
Il segmento includerà una breve presentazione del Sig. Climaco, seguita da una sessione di domande e risposte interattive. Gli investitori possono inviare domande in diretta durante l'evento o in anticipo via email a cnsp@jtcir.com. La diretta video sarà disponibile sul sito web dell'azienda, con un replay accessibile per 90 giorni dopo la presentazione.
CNS Pharmaceuticals (NASDAQ: CNSP), una empresa biofarmacéutica centrada en el desarrollo de tratamientos novedosos para el cáncer cerebral y del sistema nervioso central, ha anunciado su participación en un segmento de Virtual Investor CEO Connect. El evento, programado para lunes 26 de agosto de 2024, a las 12:00 PM ET, contará con la presencia del CEO John Climaco.
El segmento incluirá una breve presentación del Sr. Climaco, seguida de una sesión interactiva de preguntas y respuestas. Los inversores pueden enviar preguntas en vivo durante el evento o con anticipación a través del correo electrónico cnsp@jtcir.com. La transmisión en vivo estará disponible en el sitio web de la empresa, y se podrá acceder a la repetición durante 90 días tras la presentación.
CNS Pharmaceuticals (NASDAQ: CNSP), 뇌 및 중추신경계 암을 위한 혁신적인 치료법 개발에 집중하는 생명공학 회사가 Virtual Investor CEO Connect 세그먼트에 참여한다고 발표했습니다. 이 행사는 2024년 8월 26일 월요일, 오후 12:00 ET에 개최되며, CEO John Climaco가 참석합니다.
세그먼트에는 Climaco 씨의 간단한 발표가 포함되며, 이후 인터랙티브 Q&A 세션이 진행됩니다. 투자자는 행사 중 실시간으로 질문을 제출하거나 cnsp@jtcir.com으로 이메일을 통해 미리 질문할 수 있습니다. 생방송 비디오는 회사 웹사이트에서 제공되며, 발표 후 90일 동안 다시 볼 수 있습니다.
CNS Pharmaceuticals (NASDAQ: CNSP), une entreprise biopharmaceutique spécialisée dans le développement de traitements novateurs pour les cancers du cerveau et du système nerveux central, a annoncé sa participation à un segment Virtual Investor CEO Connect. L'événement, prévu pour lundi 26 août 2024, à 12h00 ET, sera animé par le PDG John Climaco.
Le segment inclura une brève présentation de M. Climaco, suivie d'une session de questions-réponses interactive. Les investisseurs peuvent soumettre des questions en direct pendant l'événement ou à l'avance par e-mail à cnsp@jtcir.com. La retransmission vidéo en direct sera disponible sur le site web de l'entreprise, avec un accès au rediffusion pendant 90 jours après la présentation.
CNS Pharmaceuticals (NASDAQ: CNSP), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuartiger Behandlungen für Gehirn- und zentralnervöse Tumoren konzentriert, hat seine Teilnahme an einem Virtual Investor CEO Connect Segment bekannt gegeben. Die Veranstaltung ist für Montag, den 26. August 2024, um 12:00 PM ET geplant und wird von CEO John Climaco geleitet.
Das Segment umfasst eine kurze Präsentation von Herrn Climaco, gefolgt von einer interaktiven Fragen- und Antwortsitzung. Investoren können während der Veranstaltung live Fragen stellen oder im Voraus per E-Mail an cnsp@jtcir.com senden. Der Live-Video-Stream wird auf der Website des Unternehmens verfügbar sein, mit einem Wiederholungslink, der für 90 Tage nach der Präsentation zugänglich ist.
- None.
- None.
Live moderated webcast with John Climaco, Chief Executive Officer of CNS Pharmaceuticals on Monday, August 26th at 12:00 PM ET
Participants have the ability to submit questions live during the Q&A portion of the segment or pre-submit questions in advance of the segment by emailing cnsp@jtcir.com
HOUSTON, TX / ACCESSWIRE / August 22, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in a Virtual Investor CEO Connect segment on Monday, August 26, 2024 at 12:00 PM ET.
As part of the virtual event, Mr. Climaco will provide a brief presentation, followed by an interactive Q&A session. Investors and interested parties will have the opportunity to submit questions live during the segment. Questions can also be pre-submitted leading up to the segment by emailing cnsp@jtcir.com. Mr. Climaco will answer as many questions as possible during the segment.
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (cnspharma.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
When is CNS Pharmaceuticals (CNSP) participating in the Virtual Investor CEO Connect segment?
Who will be representing CNS Pharmaceuticals (CNSP) at the Virtual Investor CEO Connect event?
How can investors submit questions for the CNS Pharmaceuticals (CNSP) Virtual Investor CEO Connect segment?
Where can I watch the CNS Pharmaceuticals (CNSP) Virtual Investor CEO Connect segment?
How long will the replay of CNS Pharmaceuticals (CNSP) Virtual Investor CEO Connect segment be available?
